Abstract:
Systemic lupus erythematosus (SLE) is a chronic autoimmune connective tissue disorder with multiorgan involvement, characterized by impaired immunologic tolerance, B-cell hyperactivation, and activation of the interferon cascade. Contemporary diagnostic approaches include expanded immunologic profiling, molecular genetic studies, and the use of biomarkers of organ damage. SLE treatment is currently shifting from nonspecific immunosuppression toward personalized targeted therapy. The introduction of biologic agents and the treat-to- target strategy has substantially improved disease prognosis.
